Research Topics
| Eduard J BeckSummaryAffiliation: Joint United Nations Programme on HIV/AIDS Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Viewpoint: a pragmatic approach to constructing a minimum data set for care of patients with HIV in developing countriesWilliam M Tierney
Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Am Med Inform Assoc 13:253-60. 2006..The proposed minimum data set will evolve over time as funding increases, care protocols change, and additional tests and treatments become available for HIV-infected patients in developing countries...
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008Eduard J Beck
NPMS HHC CIC, Coordinating and Analytic Centre, London, United Kingdom
PLoS ONE 7:e47376. 2012....
Counting the cost of not costing HIV health facilities accurately: pay now, or pay more laterEduard J Beck
Office of the Deputy Director, Programme Branch, UNAIDS Secretariat, Geneva, Switzerland
Pharmacoeconomics 30:887-902. 2012....
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008Eduard J Beck
NPMS HHC CIC, Coordinating and Analytic Centre, London, United Kingdom
PLoS ONE 6:e27830. 2011..Few studies have calculated the use, cost and cost-effectiveness of routine treatment and care before starting cART and starting cART above and below CD4 200 cells/mm3...
Modeling the cost-effectiveness of health programs: HIV testing and early treatment in the USAEduard J Beck
Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Future Microbiol 6:725-9. 2011..of an expanded screening and treatment program in the USA but how good was their model, how can modeling exercises assist policy-makers in answering these difficult questions and what are some of the broader implications?..
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006Eduard J Beck
NPMS HHC Coordinating and Analytic Centre, London, United Kingdom
PLoS ONE 6:e20200. 2011..Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996-2006...
Protecting HIV information in countries scaling up HIV services: a baseline studyEduard J Beck
Programme Branch, UNAIDS, Geneva, Switzerland
J Int AIDS Soc 14:6. 2011..We set out to assess the extent that countries scaling up HIV services have developed and implemented guidelines to protect the confidentiality and security of HIV information...
The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008Eduard J Beck
UNAIDS Secretariat, Geneva, Switzerland
Curr Opin HIV AIDS 5:215-24. 2010..Articles were identified using specific databases and scored, based on explicit criteria relating to the services covered, utilization data, cost data used and quality of the study...
Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countriesEduard J Beck
Evidence, Monitoring and Policy Department, UNAIDS, Geneva, Switzerland
AIDS 22:S75-85. 2008..It also summarizes global initiatives that enable countries to develop their own HIV monitoring and evaluation systems and to generate relevant, robust and up-to-date strategic information...
Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)E J Beck
NPMS HHC Coordinating and Analytic Centre, UK
Int J STD AIDS 19:297-304. 2008....
Rising population cost for treating people living with HIV in the UK, 1997-2013Sundhiya Mandalia
NPMS HHC Coordinating and Analytic Centre, London, United Kingdom
PLoS ONE 5:e15677. 2010..The number of people living with HIV (PLHIV) is increasing in the UK. This study estimated the annual population cost of providing HIV services in the UK, 1997-2006 and projected them 2007-2013...
National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?Eduard J Beck
HIV Department, World Health Organization, Geneva, Switzerland
AIDS 20:1497-502. 2006..To investigate the existence of national adult antiretroviral therapy (ART) guidelines in 43 World Health Organization (WHO) '3 by 5' focus countries and compare their content with the 2003 WHO ART guidelines...
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010Sundhiya Mandalia
Department of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom
PLoS ONE 7:e29844. 2012..Few LTNP and HIC identified in this and other studies, endorse the need for universal definitions to facilitate comparison...
Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspectsMaarten J Postma
Groningen University
Expert Opin Pharmacother 5:521-8. 2004....
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001Eduard J Beck
Departement de sante publique de Montréal centre, Montreal, Quebec, Canada
AIDS 18:2411-8. 2004..To estimate the cost-effectiveness ratio of highly-active antiretroviral therapy (HAART) in Canada...
Cost-effectiveness of highly active antiretroviral therapy in South AfricaMotasim Badri
Department of Medicine, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
PLoS Med 3:e4. 2006..Little information exists on the impact of highly active antiretroviral therapy (HAART) on health-care provision in South Africa despite increasing scale-up of access to HAART and gradual reduction in HAART prices...
Cost and cost-effectiveness of antiretroviral therapy for HIV infection in SingaporeNicholas I Paton
Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
Int J STD AIDS 17:699-705. 2006..Dual ART therapy and HAART were cost-effective interventions in Singapore. Cost-effectiveness is likely to improve if drug prices continue to decrease...
The economic profile of antenatal HIV testing: pharmaceutical and methodological considerationsMaarten J Postma
AIDS 17:755-7. 2003
